Survival, Pathologic Response, and Genomics in CALGB 40601 (Alliance), a Neoadjuvant Phase III Trial of Paclitaxel-Trastuzumab With or Without Lapatinib in HER2-Positive Breast Cancer.

Survival, Pathologic Response, and Genomics in CALGB 40601 (Alliance), a Neoadjuvant Phase III Trial of Paclitaxel-Trastuzumab With or Without Lapatinib in HER2-Positive Breast Cancer. J Clin Oncol. 2020 12 10; 38(35):4184-4193.

View in: PubMed

subject areas

Adult
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols
Breast Neoplasms
Female
Humans
Middle Aged
Neoadjuvant Therapy
Neoplasm Staging
Paclitaxel
Receptor, ErbB-2
Survival Analysis
Transcriptome
Trastuzumab
Young Adult

authors with profiles

Olwen Hahn
Mei-Yin Polley